Janssen Submits Application to U.S. FDA to Expand Indication for Daratumumab (DARZALEX®)
Janssen Biotech, Inc. announced today a supplemental Biologics License Application (sBLA) for daratumumab (DARZALEX®) has been submitted to the U.S. Food and Drug Administration (FDA).
Janssen
In The News
American Society of Hematology 2016 Annual Meeting American Society of Hematology 2016 Annual Meeting American Society of Hematology 2016 Annual Meeting American Society of Hematology 2016 Annual Meeting American Society of Hematology 2016 Annual Meeting